Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI
Authors' conclusion
Compared with ramipril, sacubitril/valsartan did not significantly decrease the risk for cardiovascular death and HF in patients with AMI complicated by left ventricular dysfunction, irrespective of the type of AMI.
Study context
- Population
- Patients with acute MI complicated by LV dysfunction and/or pulmonary congestion and ≥1 risk-enhancing factor4,291 (75.8%) STEMI
- Participants
- 5,661 patients
- Comparison
- Sacubitril/valsartan vs ramipril, by acute myocardial infarction (AMI) type
- Primary endpoint
- CV death or incident heart failure (HF)
Methodological detailsprespecified analysis, stratified by AMI type
- Prespecified analysis
- Stratified by AMI type
Primary result
As reported in the abstract
CV death or incident HF, by AMI type
Sacubitril/valsartan vs RamiprilHazard ratio (95% CI)P value
STEMI: 10% vs 12%
0.87(0.73–1.04)
P = 0.13NSTEMI: 17% vs 17%
0.97(0.75–1.25)
P = 0.80Further findings
| Outcome | Adjusted HR (95% CI) | P value | |
|---|---|---|---|
| Primary outcome, NSTEMIvs STEMIBorderline statistical significance | 1.19 (1.00–1.41) | P = 0.05 | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Angiotensin Receptor-Neprilysin Inhibition in Patients With STEMI vs NSTEMI. J Am Coll Cardiol. Published 5 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →